Clinical trial · Interventional
CKD-702 Plus Irinotecan in Gastric Cancer
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET
NCT05750290CI-TRIAL-00064374unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CKD-702 in combination with irinotecan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CKD-702 in combination with irinotecan
- interventionNames
- Drug: CKD-702 in combination with irinotecan
Primary outcomes (1)
- measure
- Best objective response rate
- timeFrame
- Through study completion, an average of 24 weeks
- description
- RECIST v1.1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Failed 2 or more lines of chemotherapy * Tumor overexpressing either MET or EGFR * Measurable lesion Exclusion Criteria: * Prior treatment with anti-MET/EGFR bispecific antibody
References
Publications (0)
Data not yet available
No reference posted for this study.